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ABSTRACT 
 
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major 
cause of maternal and perinatal morbidity and mortality. It is thought to occur due to 
abnormal placentation characterised by poor trophoblastic invasion resulting in 
oxidative stress and release of factors that promote endothelial dysfunction and 
inflammation. The current approach of screening for PE is to identify risk factors from 
maternal demographic characteristics and medical history. In the United Kingdom, 
the National Institute for Health and Clinical Excellence (NICE) has issued guidelines 
recommending that women should be considered to be at high risk of developing PE 
if they have any 1 high-risk factor or any 2 moderate-risk factors. With this approach, 
defined by NICE, at a screen positive rate of 11%, the detection rate (DR) for total 
PE is 35%. Such a screening approach has two main limitations. Firstly, it does not 
provide individualised, patient specific results and secondly, it does not allow the 
integration of biomarkers for improving the performance of the screening test. 
However, the integration of such biomarkers is essential in achieving an effective 
screening strategy for PE. 
Objectives: The aims of the papers included in this thesis are firstly, to identify and 
quantify the effects of variables from maternal characteristics and medical history on 
specific biochemical markers, secondly to present a model for standardising 
biochemical marker measurements in all three trimesters of pregnancy into multiples 
of the normal median (MoM) values, thirdly to summarize the distribution of MoM 
values in pregnancies with normal outcomes and those that subsequently develop 
PE and fourthly, to examine the potential improvement in performance of screening 
for PE at 30-34 weeks’ gestation by maternal factors alone with the addition of 
biophysical and biochemical markers. 
Methods: The data for this thesis were derived from prospective screening of 
women with singleton pregnancies attending for three routine hospital visits at 12, 22 
and 32 or 36 weeks’ gestation. We have recorded a series of maternal 
characteristics and history, measured the maternal weight and height as well as the 
uterine artery pulsatility index (UTPI), mean arterial pressure (MAP), serum 
concentration of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 
(sFLIT-1). The pregnancy outcomes were obtained from the hospital maternity 
records or the general medical practitioners of the women. Bayes theorem was used 
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to combine the a priori risk from maternal factors with various combinations of 
biomarker MoM values. The potential value of biophysical and biochemical markers 
in improving the performance in screening for PE were evaluated. 
Results: Firstly, in pregnancies that developed PE, serum PlGF is decreased, while 
sFLIT-1, MAP and UTPI were increased, secondly, the separation in MoM values 
from normal is greater with earlier than later gestational age at which delivery for PE 
is necessary and thirdly, the slope of the regression lines of PlGF MoM with 
gestational age at delivery in pregnancies that develop PE increases with gestational 
age at screening. Combined screening at 30-34 weeks’ gestation by maternal 
factors, MAP, UTPI, PlGF, and sFLIT-1 predicted 98% (95% confidence interval, 88-
100%) of preterm PE and 49% (95% confidence interval, 42-57%) of term PE, at a 
false positive rate of 5%.  
Conclusions: This thesis has demonstrated that biophysical and biochemical 
markers increase significantly the performance of screening for PE and as a result 
the timing and content of clinical visits can be defined by the patient-specific risk of 
developing the disease. The vast majority of women would be screened low risk and 
these can follow the routine antenatal care, whereas those few who are high risk 
could be directed to a more specialized pathway, where early therapeutic 
interventions prophylactically may lead to the prevention of the disease and close 
follow-up will reduce the adverse consequences of PE.  
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1.1     OVERVIEW 
 
Preeclampsia (PE) remains a leading cause of maternal perinatal morbidity and 
mortality complicating around 2-3% of pregnancies (World Health Organisation, 
2005; Cantwell et al., 2011; Duley, 2009; Confidential Enquiry into Maternal and 
Child Health; 2008). Maternal organ dysfunction is a known complication of PE 
involving the kidneys with increased serum creatinine concentration, the liver with 
elevated transaminases, neurological complications such as hyperreflexia, severe 
headache accompanied with visual scotoma, blindness, stroke or eclampsia, and 
haematological complications characterised by low platelet counts. 
 
The aetiology of PE is still unclear but it has been linked to abnormal placentation 
due to impaired trophoblastic invasion of the spiral arteries (Khong et al., 1986; Lyall, 
2002.) In pregnancies which are not complicated by PE there is an increased 
capacitance of the spiral arteries mainly due to the replacement of endothelial 
smooth muscle by trophoblasts. This physiological process results in a high utero-
placental vascular capacitance while at the same time impedance to blood flow is 
greatly decreased (Sagol et al., 1999). 
 
One of the most important features of PE is elevated blood pressure (BP) as well as 
proteinuria after 20 weeks’ of gestation. Thus the BP should be measured at the 
booking visit, as early as possible, and during the course of pregnancy. In addition, a 
detailed maternal medical history should be obtained in order to identify risk factors 
for the development of PE.  
 
All women, in the hospitals where I am a research fellow, are attending for three 
routine visits. In the first visit, at 11+0-13+6 weeks’ gestation, we recorded maternal 
characteristics and medical history and performed combined screening for 
aneuploidies. The second visit, at 19+0-24+6 weeks’ gestation, and third visit, initially 
at 30+0-34+6 weeks and subsequently at 35+0-37+6 weeks, included ultrasound 
examination of the fetal anatomy and estimation of fetal size. Biophysical markers 
such as uterine artery pulsatility index (UTPI) are routinely measured. Maternal blood 
samples were also taken for analysis for various biochemical markers. These 
assessments are carried out by several research fellows including myself. 
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I have been prospectively collecting all these data including pregnancy outcomes as 
well as ensuring quality controls of these collections. I was involved in training of 
junior research fellows in obtaining ultrasound measurements and individual operator 
distributions were produced. Further training was provided for operators whose 
distributions were inappropriate. In cases where hypertensive disorders were 
reported, maternal notes have been evaluated to ensure data quality. I liaised with 
the National Ethics Committee for ethical approval and worked closely with the 
Research and Development Department to keep study documents up to date. I was 
responsible for maintaining the storage of samples in freezers, arranging the medical 
transfer agreements and I also maintained the database for samples stored for 
research.  
 
1.2   OVERALL AIMS OF THE THESIS 
 
This thesis aims to develop a new method of screening for PE during the course of 
pregnancy that will identify the majority of women that will develop PE. The rationale 
for such early identification of high-risk pregnancies is that treatment at this stage, 
with such drugs as low-dose aspirin, can potentially prevent the development of the 
disease. Screening in the second trimester will essentially re-categorise women into 
high risk or low risk groups. Some of the previous high risk women will be classified 
at this point as low risk maybe because the pharmacological intervention has 
managed to produce healthy placentation, and these women will follow the routine 
antenatal care path. Previously low risk women might now be classified as high risk 
and thus be closely monitored for early identification of the signs of the disease. In 
the third trimester, and in particular at 30-34 week’s gestation, we will screen women 
and depending on their result we will aim to decide when, where and by which 
method we will deliver the baby. 
The aims of the papers included in this thesis are:    
• effectively use Bayes theorem to combine maternal characteristics with 
biophysical and biochemical markers  
• produce patient specific risks 
• identify and quantify the effects of variables from maternal characteristics and 
medical history on specific biochemical markers 
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• present a model for standardising biochemical marker measurements in all 
three trimesters of pregnancy into multiples of the normal median (MoM)   
• summarize the distribution of MoM values in pregnancies with normal 
outcomes and those that subsequently develop PE 
• investigate the performance of our screening method throughout the course of 
pregnancy 
• examine the potential improvement in performance of screening for PE at 30-
34 weeks’ gestation by maternal factors alone with the addition of biophysical 
and biochemical markers. 
 
1.3    DEFINITION OF PREECLAMPSIA 
 
PE is a disorder in pregnancy characterised by hypertension and proteinuria in a 
previously normotensive woman. There are several definitions for the diagnosis of 
PE but the one that is widely used is that of the International Society for the study of 
Hypertension in Pregnancy (ISSHP) (Davey and MacGillivray, 1988; Brown et al., 
2001, Tranquilli et al., 2014). Thus according to the ISSHP, PE is defined as a 
systolic blood pressure of ≥140mm Hg and/or diastolic blood pressure of ≥90mm Hg 
on at least 2 occasions 4 hours apart that develops after 20 weeks’ gestation in a 
previous normotensive woman and proteinuria of ≥300mg in 24 hours or 2 readings 
of at least ++ on dipstick analysis of midstream or catheter urine specimens, if no 24-
hour collection is available. 
 
In PE, hypertension develops as a result of vasoconstriction and reduced peripheral 
vascular compliance. It is an important sign of PE, since it is an early indication of the 
disease. This highlights the importance of monitoring BP during antenatal care. 
Usually the first BP measurement is the highest while the subsequent measurements 
become lower since the patient becomes more familiar to the procedure (Poon et al., 
2012). Thus it is recommended by professional bodies that a series of blood 
pressure measurements should be made until a level of stability is achieved 
(National Heart Foundation of Australia, 2004; Pickering et al., 2005). Accurate 
assessment of BP has also been hindered by the considerable variability that BP 
exhibits within each individual operator. The gold standard in clinical practice is the 
use of sphygmomanometers but there are concerns for their clinical performance 
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(Markandu et al., 2000). In these studies, mean arterial pressure (MAP) was 
measured at each visit. The use of validated automated devices allows simple, 
standardised, and repeated measurements to be taken. It also addresses many of 
the errors associated with the conventional sphygmomanometer but their use still 
requires the selection of the correct cuff size, proper patient positioning and at least 
two measurements should be taken from each arm simultaneously. 
 
1.4    PATHOGENESIS OF PREECLAMPSIA 
 
The pathogenesis of PE is still unclear but it is believed to occur due to the impaired 
invasion of trophoblasts in the spiral arteries. These impairment results in an 
endothelial dysfunction which manifests itself in clinical signs and symptoms 
frequently encountered in preeclamptic women. 
 
The placenta is mainly formed by the trophoblasts. The trophoblasts themselves can 
be divided into syncytiotrophoblasts and cytotrophoblasts. At around 11-12 days of 
gestation the syncytiotrophoblasts erode in the endothelial level of the maternal 
capillaries to establish the uteroplacental circulation. Later on, the cytotrophoblasts 
invade the syncytiotrophoblasts forming primary villi. During the third week of 
pregnancy the cytotrophoblasts perforate the endometrium while having an outer 
covering by the syncytiotrophoblasts. Extraembryonic mesoderm which passes 
through the cytotrophoblasts forms the secondary villi. Finally, tertiary villi are 
produced by the differentiation of their vessels at the level of the extraembryonic 
mesoderm. The trophoblastic invasion takes place in two distinct stages of 
pregnancy, the first very early as described above while the second at around 14 to 
16 weeks’ gestation (Robillard, 2002). The result of this physiological mechanism is 
to convert these high resistance muscular vessels to low resistance vessels, 
ensuring sufficient blood supply to the developing fetus (Brosens et al., 1972). 
Failure of the physiological invasion and remodelling of the spiral vessels result in 
vessels of smaller diameter producing placental ischemia and poor perfusion. 
 
Placental, endothelial and genetic factors as well as immunological maladaptation 
are believed to be involved in the pathogenesis and subsequent development of PE.  
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1.4.1 PLACENTAL FACTORS 
  
It has been demonstrated that trophoblastic invasion of spiral arteries might play a 
role in the pathogenesis of PE. Moreover, the degree of invasion seems to be of 
interest since in cases with PE only the decidual portion of the vessels has been 
invaded while in cases unaffected by PE the trophoblastic invasion had reached the 
myometrial portion of the spiral arteries (Brosens et al., 1972; Meekins et al., 1994a). 
There is an association between the severity of histological changes in spiral 
arteries, the impedance to uterine artery blood flow and the severity of PE. It has 
been documented that the more advanced the histological changes in the utero-
placental circulation the higher the UTPI, the more severe and the earlier the onset of 
the disease suggesting that there is an increased resistance in the blood flow in the 
uterine arteries suppling the placenta (Olofsson et al., 1993; Meekins et al., 1994a). 
 
Another interesting element in the pathogenesis of PE is the observation of the 
presence of acute atheromata in the utero-placental circulation (Sheppard and 
Bonnar, 1981).  
Upon histological examination of the placenta and its vascular bed, it has been 
observed the presence of fibrinoid necrosis which in turn stimulated the chemotaxis 
of macrophages which appeared to be lipid laden as well as mononuclear cellular 
infiltrates (Pijnenborg et al., 1991). In addition, there has been an increased 
deposition of lipoprotein in arterial walls as well as micro-thrombi formation which 
resulted in placental infarctions. These histological findings were not only observed in 
cases with PE but also in cases with recurrent miscarriages, pregnancies 
complicated with fetal growth restriction as well as pregnancies of women with 
antiphospholipid syndrome (Meekins et al., 1994b; Salafia et al., 1995). 
  
1.4.2 ENDOTHELIAL DYSFUNCTION 
 
It has been suggested that endothelial dysfunction plays a major role in the 
development of PE. This is essentially the result of a cascade involving primarily an 
increased vascular resistance which leads to placental hypoxia and ischemia. These 
in turn favour the release of reactive oxygen species increasing substantially the 
oxidative stress on the endothelium. These mechanisms result in a profound 
                                                                                                                                
 
	
15	
	
intravascular inflammatory response and a consequent activation or repression of 
endothelial cell function (Redman and Sargent, 2003; Myatt and Webster, 2009; 
Saito and Nakashima, 2014).  
 
These series of changes on the endothelial level cause altered levels of angiogenic 
and anti-angiogenic proteins. Vascular endothelial growth factor (VEGF) and soluble 
VEGF receptor-1 also known as sFLT-1 are examples of such proteins. This protein 
imbalance leads to further dysfunction of the endothelium (Luttun et al., 2002; 
Maynard et al., 2003; Widmer et al., 2007; Murphy et al., 2013). 
 
PlGF, a glycosylated dimeric glycoprotein, is a member of the vascular endothelial 
growth factor subfamily. It binds to vascular endothelial growth factor receptor-1 
which has been shown to rise in pregnancy. PlGF is synthesized in villous and 
extravillous cytotrophoblasts and has both vasculogenetic and angiogenetic 
functions. It is believed to contribute a change in angiogenesis from a branching to a 
non-branching phenotype controlling the expansion of the capillary network. Its 
angiogenetic abilities have been speculated to play a role in normal pregnancy and 
changes in the levels of PlGF or its inhibitory receptor have been implicated in the 
development of PE (Maynard et al., 2003; Ahmad and Ahmed, 2004; Levine et al., 
2004; Stepan et al., 2007). PE is associated with reduced placental production of 
PlGF and these reduced levels of serum PlGF precede the clinical onset of the 
disease and are evident from both the first and second trimesters of pregnancy (Su 
et al., 2001; Tidwell et al., 2001; Tjoa et al., 2001; Polliotti et al., 2003; Krauss et al., 
2004; Thadhani et al., 2004; Akolekar et al., 2008; Crispi et al., 2008; Erez et al., 
2008).  
 
 sFLT-1, is a circulating anti-angiogenic protein implicated in the pathogenesis of PE. 
It is expressed at very high levels in the trophoblast and its production is highly 
increased in hypoxic conditions. The concentration of sFLT-1 is increased in the 
placenta and serum of women with PE and exogenous sFLT-1 administered to 
pregnant rats induces hypertension, proteinuria and glomerular endotheliosis 
(Maynard et al., 2003). There is also evidence that the levels of serum sFLT-1 are 
increased in the few weeks preceding the clinical onset of PE and consequently 
sFLT-1 may be a useful biochemical marker in screening for PE (Levine et al 2004; 
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Chaiworapongsa et al 2011; Verlohren et al., 2012; Rana et al.,2012; Lai et al., 
2014). 
  
Another important characteristic of endothelial dysfunction is the resulting 
vasospasm which induces platelet activation with a subsequent dysfunction and 
thrombocytopenia (Romero et al., 1988). In addition, there is a profound decrease in 
platelet size, life span and imbalance in the proteins produced and released by the 
platelets such as thromboxane and prostacyclin (Walsh, 1985). More specifically 
thromboxane levels, which is a known vasoconstrictor increase, while prostacyclin 
levels, responsible for vasodilation decrease. This is further demonstrated by the 
decreased metabolite levels of prostacyclin in maternal urine and blood.  
 
The overall result of endothelial dysfunction is an alteration of angiogenic and anti-
angiogenic proteins which leads to platelet dysfunction and a subsequent 
vasoconstriction which ultimately favours the formation of micro-thrombi (Romero 
and Duffy, 1980).  
 
1.4.3 GENETIC AND IMMUNOLOGICAL FACTORS 
 
It has been suggested that a genetic predisposition might be involved in the 
development of PE. Several studies have shown that women with a positive family 
history have a threefold risk for developing the condition compared to those without a 
family history of PE (Arngrimsson et al., 1990; Duckitt and Harrington 2005). 
 
One or more genes or alleles may increase the risk of PE by either regulating blood 
pressure (BP) and/or modifying placental function (Cooper and Liston 1979; Chesley 
and Cooper, 1986). It is also believed that there is a linkage between PE and genes 
coding for angiotensinogen, tumour necrosis factor-a (TNF-a) and factor V Leiden 
(Morgan et al., 1999; Benedetto et al., 2002). 
 
Two meta-analysis studies have suggested that there is a role for thrombophilia 
genes in severe PE as well as a 2-fold increase for developing the disease in the 
presence of a prothrombin polymorphism (Wang et al., 2014; Human Genome 
Epidemiology Review). Despite the fact that associations between gene 
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polymorphisms and PE has been documented by these studies, the need for larger 
studies is evident. 
 
The placenta is formed from fetal tissues thus it has both maternal and paternal 
derived antigens. In pregnancies which are unaffected by PE it seems that the 
maternal immune system is tolerant to fetal antigens and any immune response 
opposes the rejection of the semi-allogenic fetus. According to some studies, in 
pregnancies with PE an immunological activation produces a reaction towards the 
fetus and the placenta and in particular against the paternal portion of the 
trophoblasts (Dekker and Robillard, 2005; Dekker et al., 1998). It has not been 
established yet if an immune reaction is a result of an abnormal placentation or if it is 
the causative mechanism of this. 
 
Epidemiological observations have shown that firstly, PE is more common in a first 
pregnancy, secondly the risk for PE decreases with subsequent pregnancies 
provided the partner is the same, thirdly changing partners increases the risk for 
developing PE and fourthly donor insemination techniques as well as oocyte 
donation increase the likelihood for the development of the condition (Robillard et al., 
1999; Li and Wi, 2000). 
 
1.5 SCREENING FOR PREECLAMPSIA 
 
The current approach of screening for PE is to identify risk factors from maternal 
demographic characteristics and medical history. In the United Kingdom, the National 
Institute for Health and Clinical Excellence (NICE) has issued guidelines 
recommending that women should be considered to be at high risk of developing PE 
if they have any 1 high-risk factor or any 2 moderate-risk factors. The high-risk 
factors are a history of hypertensive disease in a previous pregnancy, chronic kidney 
disease, autoimmune disease, diabetes mellitus, or chronic hypertension; the 
moderate-risk factors are first pregnancy, maternal age of >40 years, inter-pregnancy 
interval of >10 years, body mass index at first visit of >35 kg/m2 or family history of 
PE. With this approach, defined by NICE, at a screen positive rate of 11%, the 
detection rate (DR) for total PE is 35%, for PE requiring delivery at <37 weeks’ is 
40% and for PE requiring delivery <34 weeks’ is 44% (Wright et al., 2015). Such a 
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screening approach has three main limitations. Firstly, it does not provide 
individualised, patient specific results. Secondly, it does not allow the integration of 
biochemical and biophysical markers for improving the performance of the screening 
test, but the integration of such biomarkers is essential in achieving an effective 
screening strategy for PE. Thirdly, this screening model treats each variable as a 
separate screening test with additive detection and false positive rates thus a large 
proportion of the population is screened positive, requiring a more frequent antenatal 
care, creating an increased strain on the healthcare system. 
 
1.5.1    BACKGROUND 
 
An alternative approach to risk assessment and screening for PE is to apply Bayes’ 
theorem to combine the a priori risk from maternal characteristics and medical history 
with the results of various combinations of biophysical and biochemical 
measurements made at different times during pregnancy, which allows estimation of 
individual patient-specific risks of PE. A fundamental component of this approach is a 
previous distribution and a survival-time model for the gestational age at delivery with 
PE (Wright et al., 2012; Akolekar et al., 2013). This approach assumes that if the 
pregnancy was to continue indefinitely, all women would experience PE, and whether 
they do so or not before a specified gestational age depends on competition between 
delivery before or after the development of the disease. In pregnancies at low risk for  
PE, the gestational age distribution is shifted to the right with the implication that, in 
most pregnancies, delivery actually will occur before the development of PE. In high 
risk pregnancies, the distribution is shifted to the left, and the smaller the mean 
gestational age the higher is the risk for PE. However, in the application of Bayes 
theorem in combined screening for PE, it is essential to standardize the measured 
values of biomarkers for any variables included in the prior model into MoM values. 
 
1.5.2    BIOCHEMICAL FACTORS 
 
A large number of biochemical markers were investigated, since they represent a 
measureable manifestation of improper placentation and the subsequent release of 
inflammatory markers. In the literature, most studies have investigated such 
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biomarkers in the 2nd trimester of pregnancy as well as in pregnancies which have 
already developed PE. 
 
It is imperative that adjustments need to be made in the maternal serum metabolite 
concentration to correct for certain maternal and pregnancy characteristics as well as 
machines and reagents used for the analysis of these markers. As a result, the 
values of biochemical markers should be expressed in MoM of the normal median. 
(Kagan et al., 2008). In the studies included in this thesis two biochemical markers 
were investigated which include PlGF and sFLIT-1. 
 
PlGF is a pro-angiogenic protein released by different cells including 
cytotrophoblasts. It is involved in the processes of angiogenesis, vasculogenesis and 
vascular permeability and it is transcribed from the PLGF gene found on 
chromosome 6 (Romero et al., 2008b).  
sFLIT-1 is produced by syncytiotrophoblasts by alternative splicing of the FLIT-1 
gene resulting in a protein which is unable to bind PLGF inside cells but instead 
remains on the cell surface resulting in an antagonistic effect to PLGF (Maynard et 
al.,2003; Levine et al.,2004; Tache et al., 2011). sFLIT-1 also compromises 
endothelial function at the level of the brain, liver and kidneys (Esser et al., 1998). By 
blocking the effects of VEGF and PLGF, sFLIT-1 leads to hypertension and 
proteinuria (Eremina et al., 2003). 
 
1.5.3   BIOPHYSICAL FACTORS 
 
Biophysical markers can be used in screening for PE since they can be correlated to 
the disease. UTPI is essentially the opposition exerted to blood flow and as 
described earlier can be a measurable manifestation of histological alteration of the 
utero-placental system. Under physiological conditions the distal branches of uterine 
arteries show a decrease in resistance as the pregnancy progresses and this can be 
demonstrated using Doppler studies (Carbillon et al., 2001). Two mechanisms have 
been suggested for the low resistance in these arteries. The first one is the 
replacement of the muscular wall of the arteries with trophoblastic cells and the 
second one is the hormonal effect exerted on the compliance of the vascular wall. 
The use of specific techniques for obtaining the UTPI measurements ensures 
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reliability of the collected data. In the studies included in this thesis UTPI was 
obtained transabdominally. The uterine arteries were identified using colour Doppler 
at the level of the internal cervical os. Then pulsed-wave Doppler was applied with 
the sample gate set at 2mm to cover the whole vessel. The angle of insonation was 
less than 30° and the peak systolic velocity was greater than 60cm/s, to ensure that 
the uterine artery, rather than the arcuate artery, was being examined. When three 
similar waveforms had been obtained consecutively the UTPI was measured and the 
mean pulsatility index of the left and right arteries was calculated (Papageorghiou et 
al., 2001). 
 
There is evidence showing that in women who will eventually develop PE, BP might 
be increased from the beginning of the pregnancy (Poon et al., 2008). A meta-
analysis showed that MAP is significantly better at predicting PE compared to 
systolic or diastolic BP. Another contradictory conclusion of this meta-analysis is that 
BP measurement is not effective for screening for PE. It is important to note that 
there have been major differences in between the studies in terms of design, sample 
size and machines used to measure the BP (Cnossen et al., 2008). 
 
This highlights the necessity of a standardised method of BP measurement. In the 
studies included in this thesis MAP was measured for each visit by validated 
automated machines. The machines were calibrated before and at regular intervals 
during the studies. For the measurements the patients were in sitting position, their 
arms were supported at the level of the heart and a small (22cm), medium (22-32cm) 
or large (33-42cm) adult cuff was used depending on the mid-arm circumference. 
After resting for 5 minutes, two recordings of BP were made in both arms 
simultaneously. The final MAP was calculated as the average of all four 
measurements (Poon et al., 2012). 
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The next chapter will address and define the contribution of maternal variables which 
influence the measured levels of PLGF and sFLIT-1 and express them in MoM 
values. 
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CHAPTER 2 
 
 
 
EFFECT OF MATERNAL FACTORS ON MARKERS OF 
PLACENTATION 
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This chapter is based on two publications. Our approach to screening for pregnancy 
complications, such as preeclampsia (PE), is to apply Bayes theorem to combine the 
a priori risk from maternal characteristics and medical history with the results of 
various combinations of biophysical and biochemical measurements made at 
different times during pregnancy (Wright et al., 2012; Akolekar et al., 2013, 
Nicolaides et al., 2011). In normal pregnancies serum biochemical marker 
concentrations are affected by the gestational age as well as maternal history and 
characteristics, including weight, racial origin and outcome of previous pregnancies 
(Pandya et al.,2012., Lai et al., 2014). Consequently, the aims of the first 2 
publications are to standardise the measured levels of soluble fms-like tyrosine 
kinase-1 (sFLT-1) and placenta growth factor (PlGF) into multiples of the median 
(MoM) values by taking into account these variables for their effective use in risk 
assessment. 
 
In the first paper maternal characteristics and medical history were recorded and 
serum PLGF was measured in women with singleton pregnancies attending for three 
routine hospital visits at 12, 22 and 32 or 36 weeks’ gestation. We measured in 
38,002 cases in the first trimester, 10,281 in the second trimester and 12,398 in the 
third trimester. Significant independent contributions to serum PLGF were provided 
by gestational age, maternal age, weight and racial origin, cigarette smoking, 
diabetes mellitus, and gestational age at delivery and birth-weight Z-score of the 
neonate in the previous pregnancy. The machine used to measure serum PlGF was 
also found to have a significant effect. Allowing for other factors, the effect of 
maternal age on PlGF changed over the three trimesters, whereas other variables 
had constant effects over the three trimesters. Random-effects multiple regression 
analysis was used to define the contribution of maternal variables that influence the 
measured serum PlGF and express the values as MoMs. The model was shown to 
provide an adequate fit of MoM values for all covariates, both in pregnancies that 
developed PE and in those without this complication. Previous studies have 
investigated the value of PlGF in screening for trisomies in the 1st trimester as well as 
small for gestational age foetuses and PE in all three trimesters (Zaragoza et al., 
2009; Pandya et al., 2012., Akolekar et al., 2008, Poon et al., 2008; Akolekar et al., 
2011; Karagiannis et al., 2011; Lai et al., 2014). In this study a larger population was 
used, developing a model which identifies variables which have effects on specific 
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gestational age and variables which have a common effect across trimesters. 
Furthermore, the effects of Diabetes Mellitus type 1 and 2 as well the outcome of the 
previous pregnancies on the measured concentrations of PLGF have been 
documented by this study. 
 
In the second publication a similar methodology was used in which maternal 
characteristics and medical history were recorded and serum sFLT-1 was measured 
in women with singleton pregnancies attending for three routine hospital visits at 12, 
22 and 32 or 36 weeks’ gestation. Serum sFLT-1 was measured in 7,066 cases in 
the first-trimester, 8,078 in the second-trimester and 10,464 in the third-trimester. 
Median levels of serum sFLT-1 showed an increasing curvilinear relationship with 
gestational age, the increase was much steeper in the third trimester than in the first 
and second trimesters, while the effects on serum sFLT-1 of variables were similar in 
all three trimesters. Serum sFLT-1 decreased with maternal weight and parity but it 
was higher in cigarette smokers and in women of Afro-Caribbean racial origin than in 
Caucasian women. In addition, the serum levels of sFLT-1 increased with the inter-
pregnancy interval and birth weight Z-score of the neonate in the previous 
pregnancy. In this paper also the model was shown to provide an adequate fit of 
MoM values for all covariates both in pregnancies that developed PE and in those 
without this pregnancy complication. Previous studies investigating sFLT-1 for the 
prediction of PE did not adjust the measured values according to maternal 
characteristics and medical history (Karumanchi 2004; Chaiworapongsa et al., 2011; 
Verlohren et al., 2012; Rana et al., 2012). The observation that sFLT-1 decreases 
with increasing maternal weight, is higher in Afro-Caribbean women than in 
Caucasian women and is lower in parous than nulliparous women has been made in 
previous studies (Lai et al., 2014). In this study though, it was also identified that 
sFLT-1 is lower with smoking, is affected by the outcome of the previous pregnancy 
in parous women and the effects of variables on sFLT-1 are similar in all trimesters. 
 
Strengths and limitations 
 
The main strength of these studies is the large number of women that were 
examined. Also women were examined on specific gestational ages which are widely 
used for routine screening for chromosomal abnormalities in the first trimester and for 
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the assessment of fetal anatomy and wellbeing in the second and third trimesters. 
The assessment and counselling can be done on the same visit since results can be 
readily available by the use of automated machines. Furthermore, the application of 
multiple regression analysis resulted in determining which maternal variables affect 
the measured levels of PlGF and sFLT-1 across all three trimesters of pregnancy. 
 
An alternative approach was to include all gestational weeks from the beginning to 
the end of the pregnancy but a more practical approach was to collect data from the 
gestational-age ranges used in routine clinical practice. 
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https://www.ncbi.nlm.nih.gov/pubmed/25653039 Tsiakkas A, Duvdevani N, Wright A, 
Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of 
pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet 
Gynecol 2015; 45:591-598. 
 
https://www.ncbi.nlm.nih.gov/pubmed/25678265 Tsiakkas A, Duvdevani N, Wright A, 
Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 in the three 
trimesters of pregnancy: effects of maternal characteristics and medical history. 
Ultrasound Obstet Gynecol 2015; 45:584-590. 
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The next chapter will address the distribution of biochemical markers across all 
trimesters of pregnancies which develop PE and examine the performance of these 
biomarkers in screening for PE. 
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CHAPTER 3 
 
 
 
EFFECT OF PLACENTATION MARKERS IN SCREENING FOR 
PREECLAMPSIA 
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This chapter is based on two publications. The incorporation of biochemical markers 
in preeclampsia (PE) screening could potentially improve the prediction of PE 
provided by maternal factors alone and in addition could provide patient specific risks 
within 40 minutes of sampling so that complete assessment and counselling can be 
undertaken in the same hospital visit.  
 
In the third publication serum PlGF was measured in 40,212 cases at 11-13 weeks, 
in 10,282 cases at 19-24 weeks, in 10,400 at 30-34 weeks and 4,043 at 35-37 
weeks; Bayes theorem was used to combine the a priori risk from maternal factors 
with serum PlGF. To provide model based estimates for the performance of 
screening, we obtained the dataset of 123,406 pregnancies including 2,748 (2.2%) 
cases of PE. This dataset was also used previously to develop a model for PE based 
on maternal characteristics and history (Wright et al., 2015; Andrietti et al., 2015). For 
the empirical performance of screening five-fold cross validation was used by models 
combining maternal characteristics and history with PlGF. This large prospective 
screening study has demonstrated firstly, that in pregnancies that developed PE, 
serum PLGF is decreased, secondly, the separation in multiples of the median 
(MoM) values from normal is greater with earlier than later gestational age at which 
delivery for PE is necessary and thirdly, the slope of the regression lines of PlGF 
MoM with gestational age at delivery in pregnancies that develop PE increases with 
gestational age at screening. The detection rate (DR) at a false positive rate (FPR) of 
10%, for PE at <32 weeks was 79% and 96% with screening at 12 and 22 weeks, 
respectively, the DR for PE at 32+0	-36+6	weeks was 57%, 69% and 90% with 
screening at 12, 22 and 32 weeks and the DR for PE at ≥37 weeks was 40%, 39%, 
54% and 64% with screening at 12, 22, 32 and 36 weeks, respectively. The 
measurement of serum PlGF improved substantially the performance of screening of 
PE provided by maternal factors alone. While several studies have shown that PlGF 
is decreased in both the 1st and 3rd trimesters of pregnancies that develop PE 
(O’Gorman et al., 2015; Akolekar et al., 2008; Akolekar et al 2011; Lai et al.,2014), in 
this study we have compared the performance of screening for early, intermediate 
and late PE by maternal factors alone and in combination with PlGF. Furthermore, 
the relationship between gestational age at screening and performance of the test 
was established. 
 
                                                                                                                                
 
	
30	
	
The same methodology was used in the fourth paper in which the distribution and 
performance in screening for PE of maternal sFLT-1 was examined. The levels of 
this biochemical marker were determined in 7,066 cases at 11-13 weeks, 8,079 
cases at 19-24 weeks, 8,472 at 30-34 weeks and 4,043 at 35-37 weeks. The 
performance of screening for PE in women requiring delivery <32, between 32 and 
36+6 weeks and >37 weeks’ gestation were estimated. In pregnancies that developed 
PE, serum soluble fms-like tyrosine kinase-1 (sFLT-1) was increased and the 
separation in MoM values from normal was greater with earlier, compared to later, 
gestational age at which delivery for PE became necessary. In pregnancies that 
developed PE, the slope of the regression lines of sFLT-1 MoM with gestational age 
at delivery increased with advancing gestational age at screening. Measurement of 
sFLT-1 at 11-13 weeks did not improve the prediction of PE achieved by maternal 
factors alone, sFLT-1 at 19-24 weeks improved the prediction of PE delivering <37 
weeks but not for PE delivering >37 weeks, sFLT-1 at 30-34 weeks improved the 
prediction of PE delivering <37 weeks and PE delivering >37 weeks and sFLT-1 at 
35-37 weeks improved the prediction of PE delivering >37 weeks. The DRs, at a 
FPR of 10%, of PE delivering <32 weeks were 52% and 65% with screening at 12 
and 22 weeks, respectively. The DRs for PE delivering between 32 and 36+6 weeks 
were 44%, 44% and 93% with screening at 12,22 and 32 weeks. The DRs for PE 
delivering >37 weeks were 37%, 37%, 52% and 69% with screening at 12, 22, 32 
and 36 weeks, respectively. Thus the performance of combined screening with 
maternal factors and serum sFLT-1 is superior for detection of early, compared to 
late, PE and improves with advancing gestational age at screening. A few studies 
have shown that sFLT-1 concentration is increased a few weeks before the 
development of the disease (Levine et al., 2004; Dong et al., 2011; Verlohren et al., 
2012; Rana et al., 2012; Lai et al., 2014). Moreover, case–control studies have 
shown that in women with PE serum sFLT-1 is elevated from the 1st trimester, 
improving the performance of screening at this stage of the pregnancy (Crovetto et 
al., 2014; Crovetto et al., 2015). In this study we have documented the performance 
of screening using maternal factors alone and in combination with sFLT-1 for early, 
intermediate and late PE. Opposite to what has been shown by the studies 
mentioned above, incorporation of sFLT-1 at 11-13 weeks’ gestation did not improve 
the prediction of PE compared to maternal factors alone. 
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Strengths and limitations 
 
Potential strengths for these studies include firstly, the examination of a large 
population of pregnant women attending for routine care secondly, data on maternal 
characteristics and history with known associations with PE have been recorded 
thirdly, since biochemical marker measurements can be performed by automated 
machines which are currently used in routine screening for aneuploidies, results can 
be available in less than one hour allowing for counselling of patients in the same 
hospital visit fourthly, the measured values of PlGF and sFLT-1 have been converted 
to MoM’s allowing for adjustment for factors that affect the measurements and fifthly, 
patient specific risks can be produced at different stages of pregnancy since Bayes’ 
theorem was used to combine the a priori risk derived from maternal factors with 
biochemical markers. A possible limitation of these studies is the potential 
overestimation of the performance of screening since the same dataset was used to 
develop the screening model. A cross validation was used to reduce this effect, 
demonstrating a good agreement between the modelled and empirical performance. 
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https://www.ncbi.nlm.nih.gov/pubmed/26582455 Tsiakkas A, Cazacu R, Wright A, 
Wright D, Nicolaides KH. Serum placental growth factor at 12, 22, 32 and 36 weeks' 
gestation in screening for preeclampsia. Ultrasound Obstet Gynecol 2015; 47:472-
477. 
 
https://www.ncbi.nlm.nih.gov/pubmed/26582564 Tsiakkas A, Mendez O, Wright A, 
Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 
36 weeks' gestation in screening for preeclampsia. Ultrasound Obstet Gynecol 2015; 
47:478-483. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                
 
	
33	
	
The next chapter will address the performance of screening for PE by a combination 
of maternal factors with early third-trimester biochemical and biophysical markers. 
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CHAPTER 4 
 
 
 
COMBINED SCREENING FOR PREECLAMPSIA AT 30-34 WEEKS’ 
GESTATION 
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This chapter is based on one publication. The objectives of third trimester screening 
for preeclampsia (PE), is to improve perinatal outcome through close monitoring of 
the high-risk population for earlier diagnosis of the clinical signs of the disease and 
selection of the appropriate, time, place and method of delivery. Thus the objective of 
the fifth publication was to develop a model of screening for PE based on a 
combination of maternal factors with early third-trimester biomarkers and in the 
estimates of performance of screening, empirical results are compared with model-
based rates. Data were collected for mean arterial pressure (MAP), uterine artery 
pulsatility index (UTPI), placenta growth factor (PlGF) and soluble fms-like tyrosine 
kinase-1 (sFLT-1) from 29,042, 30,935, 10,123 and 8,264 women respectively, 
attending for their routine hospital visits at 30-34 weeks’ gestation. Bayes theorem 
was used to combine the a priori risk from maternal factors with various combinations 
of biomarkers (Wright et al., 2015; O’Gorman et al.,2016; Gallo et al., 2015). The 
measured levels of biomarkers are affected by variables from maternal 
characteristics and history and thus their levels were standardised into multiples of 
the median (MoM) values (Wright et al.,2015; Tayyar et al., 2015; Tsiakkas et al., 
2015a; Tsiakkas et al., 2015b). The performance of screening for PE requiring 
delivery at <37 weeks and >37 weeks’ gestation and within 4 and 6 weeks of 
assessment were determined firstly by examining the empirical results in 7927 
pregnancies with complete data on MAP, UTPI, PLGF and sFLT-1, secondly by 
examining the empirical results  using all available data for each biomarker, and 
thirdly by modelling, whereby values on biomarkers were simulated for our 123,406 
singleton pregnancies with available data on maternal factors (Gallo et al., 2015).We 
concluded that in pregnancies that developed PE, the values of MAP, UTPI and 
sFLT-1 were increased and PlGF was decreased. For all the biomarkers the 
deviation from normal was greater for preterm than term PE and therefore the 
performance of screening was inversely related to the gestational age at which 
delivery was necessary for maternal and/or fetal indications. Screening by maternal 
factors alone predicted 47% and 37% of PE at <37 and >37 weeks’ gestation, 
respectively, at a false positive rate (FPR) of 10%. The respective values for 
combined screening with maternal factors, MAP, UTPI, PLGF and sFLT-1 were 99% 
and 49%. 
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Strengths and limitations 
 
A large population of women attending for routine care is a gestational age widely 
used for the assessment of fetal growth was used. The a priory risk was generated 
from the maternal characteristics and medical history allowing the calculation of 
patient-specific risks using Bayes theorem. Furthermore, the methods used in 
obtaining the measurements of all the biophysical markers were well established. 
The measurements were obtained by appropriately trained doctors thus ensuring 
reliable datasets. Equally important is the prompt availability of biochemical results 
by automated machines. Lastly, biochemical and biophysical markers have been 
expressed in MoM thus allowing for adjustment of factors affecting the 
measurements. A limitation of this study is that some findings rely on modelling. A 
10-fold cross-validation was used on the empirical data, reducing bias. In addition, 
the empirical and modelled performance was compatible which is reassuring. 
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https://www.ncbi.nlm.nih.gov/pubmed/26875953 Tsiakkas A, Saiid Y, Wright A, 
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The next chapter involves the discussion and the conclusions of all studies presented 
in previous chapters. 
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CHAPTER 5 
 
 
 
 DISCUSSION AND CONCLUSIONS 
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5.1    Implications for clinical practice 
 
Preeclampsia (PE) is a major cause of morbidity and mortality for both the mother 
and the baby. The current screening guidelines in the United Kingdom issued by the 
National Institude for Health and Clinical Excellence (NICE), unfortunately result in 
poor detection of women who will develop the disease (Wright et al 2015; O’Gorman 
et al., 2016; Gallo et al., 2015). This is mainly because of the methodology used, 
which involves only maternal medical history and characteristics and their 
incorporation into a risk scoring system, which treats each risk factor as a separate 
screening test with additive detection rates (DR) (Wright et al.,2015; O’Gorman et al., 
2016; Gallo et al., 2015). Depending on this score the intensity of prenatal care is 
adjusted accordingly. In the late second or third trimester of pregnancy current 
prenatal care involves screening for PE based on the demonstration of elevated 
blood pressure (BP) and proteinuria during a routine clinical visit. The objective of 
minimizing adverse perinatal outcomes can be achieved using an alternative method 
of screening which will produce patient-specific risks. According to these risks the 
appropriate intensity in maternal and fetal monitoring, time and place of delivery and 
even pharmacological intervention could be determined. It has been suggested from 
meta-analysis studies that initiation of aspirin from early pregnancy can reduce the 
incidence of PE (Bujold et al.,2010; Roberge et al., 2012a and 2012b). 
 
Bayes’ theorem states the probability of an event, based on conditions that might be 
related to the event. Another approach to screening which is based on Bayes’ 
theorem and allows estimation of individual patient-specific risks involves the 
combination of maternal characteristics and history with various biochemical and 
biophysical markers (Wright et al.,2015; O’Gorman et al., 2016; Gallo et al., 2015). 
Such an approach is based on a survival-time model which treats the gestation at the 
time of delivery for PE as a continuous rather than a categorical variable. Thus PE 
could be considered as a single pathophysiological entity with a wide spectrum of 
severity manifested in gestational age at which delivery becomes necessary for 
maternal and/or fetal indications. Essentially this gives the option to clinicians and 
researchers to select their own gestational age cut-off to define the high risk group 
that could potentially benefit from therapeutic interventions. This thesis has shown 
that the screening performance of such an approach is improved compared to the 
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model based series of maternal characteristics alone. This concept is well accepted 
in screening for aneuploidies in which a combined risk cut-off is used to guide 
pregnancy management thus this philosophy could be adopted in screening for PE.  
 
There is a significant effect of maternal characteristics on the concentration of 
biochemical markers in normal pregnancies and thus the adjustment for these 
characteristics before comparison with pregnancies affected with PE is needed 
(Kagan et al., 2008a).  The first two publications included in this thesis have defined 
the contribution of these maternal characteristics on the measured concentrations of 
placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT-1) and 
converted them into multiples of the median (MoM) so that they can be used in the 
model described before. In addition, the distribution of both PlGF and sFLT-1 in 
normal pregnancies and those that developed PE was examined. 
 
In the third publication it was demonstrated that PlGF improves the prediction of PE 
provided by maternal factors alone. In pregnancies which developed PE serum PlGF 
was decreased and the performance of the test is higher for early onset PE than late 
onset PE. It has also been shown that the performance of screening from PE 
delivering before 32 weeks is superior with screening at 22 than at 12 weeks, the 
performance of screening at 32 to 36+6 weeks is superior with screening at 32 than 
at 22 or 12 weeks and the performance of screening for PE delivering after 37 weeks 
is superior with screening at 36 weeks than at earlier gestations. This study has 
essentially documented the relationship between gestational age at screening and 
performance of the test using PLGF and maternal factors. 
 
In the fourth publication it was demonstrated that incorporation of sFLT-1 in the 
screening model greatly improves its’ performance in the 2nd and 3rd trimesters of 
pregnancy compared to the prediction of PE by maternal factors alone. Serum sFLT-
1 increases in pregnancies that develop PE and the performance of the test is higher 
for early onset PE than late onset PE. In addition, the findings of this study suggest 
that the performance of screening for PE delivering at 32 to 36+6 weeks is superior 
with screening at 32 than at 22 weeks and the performance of screening for PE 
delivering after 37 weeks is superior with screening at 36 weeks than at earlier 
gestations. Case-control studies have shown that serum sFLT-1 is increased from 
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the 1st trimester of pregnancy and that the incorporation of this biomarker in the 
screening model increases the performance of the test (Crovetto et al., 2014; 
Crovetto et al., 2015). The relationship between gestational age at screening and the 
performance of the screening test using sFLT-1 and maternal factors has been 
documented in this study. 
 
In the fifth publication, we have shown that in pregnancies that develop PE, the early 
3rd trimester values of uterine artery pulsatility index (UTPI), mean arterial pressure 
(MAP) and sFLT-1 are increased and PlGF is decreased and the performance of 
screening is better for preterm than term PE. Screening for PE at 30-34 weeks’ 
gestation with the combination of biophysical and biochemical factors used in this 
study could predict at 5% false positive rate (FPR), 98% of preterm PE and 49% of 
term PE. These results are superior to the ones achieved by screening at 11-13 or 
19-24 weeks (O’Gorman et al., 2015; Gallo et al., 2015).  This study has shown also 
that a screening positive result at 5% FPR is associated 20 –fold and 11-fold 
increase in the odd ratios of preterm PE and term PE respectively. In the same time 
as screen negative result for the same FPR translates to a 42-fold and 2-fold 
decrease in the odds ratios of preterm and term PE respectively. 
 
PE can have different levels of severity depending especially on the gestational age 
it develops. Mild forms of preeclampsia will manifest through hypertention, 
proteinuria, heartburn, nausea or vomiting, oedema of feet, hands, face and ankles, 
as well as severe headaches, and vision problems. These symptoms apart from their 
somatic effects, have also psychological effects since they cause anxiety and 
concern to the pregnant woman. In cases where PE develops in the early second 
trimester of pregnancy it might cause severe complications to both the mother and 
the fetus. Eclampsia is one of a series of complications of PE and it includes 
convulsions. Most women recover completely but a small percentage of these 
women might develop permanent disability, brain damage or even death. HELLP 
syndrome is another complication of the disease involving haemolysis, elevated liver 
enzymes and low platelets, leading to liver and kidney failure as well as pulmonary 
oedema. PE is also accompanied by an increased risk for stroke due to the 
increased blood pressure during the course of the disease. In severe PE babies 
might need to be delivered prematurely leading to the development of neonatal 
                                                                                                                                
 
	
43	
	
respiratory distress syndrome due to inadequate development of the lung alveoli. In 
addition, the incidence of stillbirths is increased in pregnancies complicated with PE. 
 
Effective screening for PE is especially important since it can greatly improve the 
outcome of pregnancies complicated with this condition. By identifying the high risk 
population from the beginning of the pregnancy we can possibly reduce the 
incidence of the PE by simply offering aspirin (Bujold et al., 2014). Furthermore, we 
can monitor the pregnancy closer by offering ultrasound scans more frequently, and 
by examining the Doppler studies, reassuring the mothers. The close monitoring of 
fetal growth and Doppler studies will enable the physician to decide when is the most 
appropriate time to deliver the baby, thus lowering the incidence of emergency 
caesarean sections and stillbirths, as well as other fetal complications. Physicians 
can consult women who screened negative and reassure them that the risk for 
developing PE is very low. Thus mothers won’t need to attend the hospital for 
unnecessary scans.  
 
Conclusively, this thesis has demonstrated that biophysical and biochemical markers 
increase significantly the performance of screening for PE and as a result the timing 
and content of clinical visits can be defined by the patient-specific risk of developing 
the disease. The vast majority of women would be screened low risk and these can 
follow the routine antenatal care, whereas those few who are high risk could be 
directed to a more specialized pathway. The patient-specific a posteriori risk for 
early, intermediate and late PE were calculated by multiplying the a priori patient 
characteristics-derived risk with the likelihood ratio of a series of biophysical and 
biochemical markers after appropriate adjustments for the inter-correlations between 
these markers. As in the cases of maternal factors the differences in biophysical and 
biochemical markers of impaired placentation between the PE and unaffected groups 
were in general more pronounced in those developing early disease compared to 
intermediate or late-PE. The major advantage of the new model, is that it offers the 
option to clinicians and researchers to select their own gestational age cut-off to 
define the high-risk group that could potentially benefit from therapeutic interventions 
starting from the first trimester of pregnancy. 
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5.2    Strengths and limitations of this thesis 
 
Strengths of this thesis include: 
• Prospective cohort studies 
• Large populations included  
• Routine care in well-defined gestational age ranges 
• Measurement of biochemical markers by automated machines currently used 
in screening for aneuploidies which provide results in 40 minutes thus 
complete assessment and counselling can take place in the same 
appointment 
• Measurement of biophysical markers such as MAP and UTPI by specific 
methodologies which ensure accurate data 
• Accurate recording of maternal characteristics and medical history in the first 
appointment 
 
Limitations of this thesis include: 
• Not using cross-sectional studies   
• Not including data of each gestational week from the beginning to the end of 
pregnancy 
• Potential overestimation of the screening performance of the model which is 
derived and tested using the same dataset 
• Some of the results rely on modelling which introduces optimistic bias  
• Need of further prospective screening studies which can potentially support 
our results 
 
5.3    Future research 
 
Future studies should define contingent strategies for the selection of patients who 
will benefit from assessment at different points in pregnancy and develop protocols 
for the effective management of the high-risk cases which will be identified through 
the screening programme. Finally, the determination if such management protocols 
will improve the perinatal outcome is something which needs to be addressed. 
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Future research is necessary to validate these algorithms in clinical practice and the 
performance of screening to be tested in different populations. If such studies 
demonstrate similar results to those of my publications, the use of Bayes theorem 
and the incorporation of maternal serum PlGF and sFLT-1 in screening for PE could 
substantially improve antenatal care with timely diagnosis and treatment of PE, which 
will potentially decrease the adverse consequences of PE for both mother and baby.  
 
Such a multicentre study involving the use of an algorithm based on Bayes’ theorem 
will undertake screening at 11-13 weeks’ gestation in 16,500 singleton pregnancies 
(SPREE- Screening programme for preeclampsia). Another multicentre study which 
is also based on the same philosophy is the ASPRE study involving several centres 
in Europe. It aims to screen 33,680 singleton pregnancies and to randomise high risk 
patients into either placebo or aspirin. This study is ongoing and results are expected by the 
end of 2016.  
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